

BTI

JP2001206856

AN 2001-570911 [65] WPIX

DNC C2001-169825

TI Use of glycogen phosphorylase for the manufacture of a medicament for the treatment of diabetic cardiomyopathy.

DC B02

IN TREADWAY, J L

PA (PFIZ) PFIZER PROD INC; (TREA-I) TREADWAY J L

CYC 33

PI AU---200116399 A 20010726 (200165)* 86

CA----2331847 A1 20010724 (200165) EN

JP--2001206856 A 20010731 (200165) 35 <--

EP----1125580 A2 20010822 (200173) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR

US--2001046958 A1 20011129 (200202)

KR--2001083148 A 20010831 (200215)

ZA---200100607 A 20020925 (200275) 78

HU---200100321 A2 20021028 (200277)

ADT AU---200116399 A 2001AU-0016399 20010123; CA----2331847 A1 2001CA-2331847
20010122; JP--2001206856 A 2001JP-0014036 20010123; EP----1125580 A2
2001EP-0300575 20010123; US--2001046958 A1 Provisional 2000US-177770P
20000124, 2001US-0767633 20010123; KR--2001083148 A 2001KR-0003820
20010126; ZA---200100607 A 2001ZA-0000607 20010122; HU---200100321 A2
2001HU-0000321 20010123

PRAI 2000US-177770P 20000124; 2001US-0767633 20010123

AN 2001-570911 [65] WPIX

AB AU 200116399 A UPAB: 20011108

NOVELTY - Treating diabetic cardiomyopathy involves administering a glycogen phosphorylase inhibitor (A).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a pharmaceutical composition comprising (A) and a carrier, excipient or adjuvant; and

(2) a kit comprising the pharmaceutical composition; and instructions for use.

ACTIVITY - Antidiabetic; Hypotensive; Cardiant; Anorectic;
Antilipemic.

MECHANISM OF ACTION - alpha 2-antagonist; PPAR- gamma agonist; Fatty acid oxidation inhibitor; alpha -glucosidase inhibitor; beta -agonist; Phosphodiesterase inhibitor; amylin antagonist; glucagon antagonist; gluconeogenesis inhibitor; Aldose reductase inhibitor; Sorbitol dehydrogenase inhibitor; Glucocorticoid receptor antagonist, NHE-1 inhibitor.

USE - In the manufacture of a medicament for treating diabetic cardiomyopathy, diabetes, cardiovascular disease, ischemic heart disease, congestive heart failure; for treating a diabetic patient who is at a risk of suffering from myocardial ischemia and reperfusion; also for treating hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, coagulopathy, cardiac contusion, myocardial infarction and small

BEST AVAILABLE COPY

vessel disease without atherosclerotic cardiovascular disease or luminal narrowing (all claimed).

ADVANTAGE - (A) prevents the patients from undergoing balloon angioplasty, bypass surgery and major non-cardiac surgery.

BEST AVAILABLE COPY